WO2001018240A3 - Diagnostic and therapeutic methods in autoimmune disease - Google Patents

Diagnostic and therapeutic methods in autoimmune disease Download PDF

Info

Publication number
WO2001018240A3
WO2001018240A3 PCT/CA2000/001043 CA0001043W WO0118240A3 WO 2001018240 A3 WO2001018240 A3 WO 2001018240A3 CA 0001043 W CA0001043 W CA 0001043W WO 0118240 A3 WO0118240 A3 WO 0118240A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
intron
polymorphism
diagnostic
gamma gene
Prior art date
Application number
PCT/CA2000/001043
Other languages
French (fr)
Other versions
WO2001018240A2 (en
Inventor
Paul Keown
Abbas Khani-Hanjani
David Hoar
Original Assignee
Univ British Columbia
Paul Keown
Khani Hanjani Abbas
David Hoar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2282062 external-priority patent/CA2282062A1/en
Priority claimed from CA 2303504 external-priority patent/CA2303504A1/en
Application filed by Univ British Columbia, Paul Keown, Khani Hanjani Abbas, David Hoar filed Critical Univ British Columbia
Priority to EP00960244A priority Critical patent/EP1212463A2/en
Priority to CA002384029A priority patent/CA2384029A1/en
Priority to JP2001521775A priority patent/JP2003508081A/en
Priority to AU72628/00A priority patent/AU7262800A/en
Publication of WO2001018240A2 publication Critical patent/WO2001018240A2/en
Publication of WO2001018240A3 publication Critical patent/WO2001018240A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

In one aspect, the invention provides a method of diagnosis. The diagnostic method may include steps of identifying a patient at risk of an arthritis, the patient having an interferon gamma gene. The patient may be tested to characterize a polymorphism in a first intron of the interferon gamma gene. The polymorphism may comprise a variable length dinucleotide repeat region within the first intron, and the dinucleotide repeat region may be located at least partly between nucleotides 1349 and 1373 in the interferon, gamma gene. The method may be carried out so as to be capable of identifying alleles such as the 126 bp allele and the 122 bp allele, as further described herein. The polymorphisms may be distinguished based on a difference in the number of CA repeats in a portion of the first intron of the interferon gamma gene. The invention may also comprise testing a patient for a polymorphism is an HLA protein (or gene), such as the HLA-DRB1 protein.
PCT/CA2000/001043 1999-09-08 2000-09-08 Diagnostic and therapeutic methods in autoimmune disease WO2001018240A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00960244A EP1212463A2 (en) 1999-09-08 2000-09-08 Diagnostic and therapeutic methods in autoimmune disease
CA002384029A CA2384029A1 (en) 1999-09-08 2000-09-08 Diagnostic and therapeutic methods in autoimmune disease
JP2001521775A JP2003508081A (en) 1999-09-08 2000-09-08 Diagnosis and treatment methods for autoimmune diseases
AU72628/00A AU7262800A (en) 1999-09-08 2000-09-08 Diagnostic and therapeutic methods in autoimmune disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CA2,282,062 1999-09-08
CA 2282062 CA2282062A1 (en) 1999-09-08 1999-09-08 Diagnostic methods in autoimmune disease
US16061899P 1999-10-20 1999-10-20
US60/160,618 1999-10-20
CA2,303,504 2000-04-10
CA 2303504 CA2303504A1 (en) 1999-09-08 2000-04-10 Diagnostic methods in autoimmune disease

Publications (2)

Publication Number Publication Date
WO2001018240A2 WO2001018240A2 (en) 2001-03-15
WO2001018240A3 true WO2001018240A3 (en) 2001-11-08

Family

ID=27171032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001043 WO2001018240A2 (en) 1999-09-08 2000-09-08 Diagnostic and therapeutic methods in autoimmune disease

Country Status (4)

Country Link
EP (1) EP1212463A2 (en)
JP (1) JP2003508081A (en)
AU (1) AU7262800A (en)
WO (1) WO2001018240A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613844D0 (en) * 2006-07-12 2006-08-23 Progenika Biopharma Sa Methods and products for in vitro genotyping
ATE550443T1 (en) * 2007-05-03 2012-04-15 Janssen Biotech Inc MATRIX MARKER MODEL AND METHOD FOR CHECKING AND TREATING RHEUMATIC ARTHRITIS
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
RU2523413C1 (en) * 2012-12-14 2014-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) DIAGNOSTIC TECHNIQUE FOR RHEUMATOID ARTHRITIS IF MUTATED CITRULLINATED VIMENTIN ANTIBODIES (Anti-MCV) ARE FOUND IN ORAL FLUID

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KHANI-HANJANI, A. ET AL.: "Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis", LANCET, vol. 356, 2 September 2000 (2000-09-02), pages 820-825, XP002172553 *
MOLKENTIN, J. ET AL.: "Molecular analysis of HLA-DRbeta and DQbeta polymorphism in Chinese with rheumatoid arthritis", ANNALS RHEUM. DIS., vol. 52, 1993, pages 610 - 612, XP001010295 *
RUIZ-LINARES, A.: "Dinucleotide repeat polymorphism in the interferon-gamma (INFG) gene", HUMAN MOLECULAR GENETICS, vol. 2, no. 9, 1993, pages 1508, XP002172554 *

Also Published As

Publication number Publication date
JP2003508081A (en) 2003-03-04
WO2001018240A2 (en) 2001-03-15
EP1212463A2 (en) 2002-06-12
AU7262800A (en) 2001-04-10

Similar Documents

Publication Publication Date Title
Baumann et al. Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions A alpha 312 and B beta 448
Hazan et al. Autosomal dominant familial spastic paraplegia is genetically heterogeneous and one locus maps to chromosome 14q
Bolos et al. Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism
Roberts et al. Exon structure of the human dystrophin gene
Abraham et al. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease
Raha-Chowdhury et al. New polymorphic microsatellite markers place the haemochromatosis gene telomeric to D6S105
Mizukl et al. A strong association between HLA‐B* 5101 and Behçet's disease in Greek patients
US5714319A (en) Method for the screening of familial hemiplegic migraine (FHM)
JP2001517067A (en) Detection of genetic predisposition for periodontal disease
WO2004075733A3 (en) Construction of a deafness gene chip
WO1996020288A8 (en) Methods of human prostate cancer diagnosis
CN110541025A (en) Detection method, primer composition and kit for Duchenne muscular dystrophy gene defect
Herbon et al. High-resolution SNP scan of chromosome 6p21 in pooled samples from patients with complex diseases
Bagnall et al. Creation of a novel donor splice site in intron 1 of the factor VIII gene leads to activation of a 191 bp cryptic exon in two haemophilia A patients
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
West et al. Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients
WO2001018240A3 (en) Diagnostic and therapeutic methods in autoimmune disease
EP2302075A3 (en) Method for typing of HLA alleles
EP1178119A2 (en) A Pcr-based multiplex assay for determining haplotype
US20040091927A1 (en) Method for the determination of data for the preparation of the diagnosis of phakomatosis
Ko et al. The G1691A mutation of the coagulation factor V gene (factor V Leiden) is rare in Chinese: an analysis of 618 individuals
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
Totaro et al. New polymorphisms and markers in the HLA class I region: relevance to hereditary hemochromatosis (HFE)
Lemmink et al. Identification of four novel mutations in the COL4A5 gene of patients with Alport syndrome
EP1262565A3 (en) Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2384029

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 521775

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000960244

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000960244

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000960244

Country of ref document: EP